- Home
- ICON vs LIPO Comparison
ICON vs LIPO Comparison
Compare ICON & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- LIPO
- Stock Information
- Founded
- ICON 2023
- LIPO 2005
- Country
- ICON Greece
- LIPO United States
- Employees
- ICON N/A
- LIPO N/A
- Industry
- ICON
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- LIPO Health Care
- Exchange
- ICON Nasdaq
- LIPO Nasdaq
- Market Cap
- ICON 3.6M
- LIPO 3.1M
- IPO Year
- ICON 2024
- LIPO 2022
- Fundamental
- Price
- ICON $0.22
- LIPO $3.13
- Analyst Decision
- ICON Strong Buy
- LIPO Strong Buy
- Analyst Count
- ICON 1
- LIPO 1
- Target Price
- ICON $7.00
- LIPO $16.00
- AVG Volume (30 Days)
- ICON 5.2M
- LIPO 6.6M
- Earning Date
- ICON 03-04-2025
- LIPO 03-07-2025
- Dividend Yield
- ICON 66.67%
- LIPO N/A
- EPS Growth
- ICON N/A
- LIPO N/A
- EPS
- ICON 0.30
- LIPO N/A
- Revenue
- ICON $4,810,000.00
- LIPO $483,533.00
- Revenue This Year
- ICON $32.17
- LIPO N/A
- Revenue Next Year
- ICON $96.55
- LIPO N/A
- P/E Ratio
- ICON $0.82
- LIPO N/A
- Revenue Growth
- ICON 5.71
- LIPO 0.78
- 52 Week Low
- ICON $0.19
- LIPO $2.21
- 52 Week High
- ICON $3.85
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- LIPO 48.17
- Support Level
- ICON N/A
- LIPO $2.82
- Resistance Level
- ICON N/A
- LIPO $4.69
- Average True Range (ATR)
- ICON 0.00
- LIPO 0.68
- MACD
- ICON 0.00
- LIPO -0.07
- Stochastic Oscillator
- ICON 0.00
- LIPO 12.18
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.